Top Non-Hodgkin Lymphoma Therapeutics Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Non-Hodgkin Lymphoma Therapeutics Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Non-Hodgkin Lymphoma Therapeutics industry players.

Non-Hodgkin Lymphoma Therapeutics Market Competitive Landscape

The global non-hodgkin lymphoma therapeutics market outlook is highly competitive, with leading players such as Roche, Novartis, Gilead Sciences, and Bristol-Myers Squibb dominating the landscape. These companies focus on innovative therapies, including immunotherapies and CAR-T cell treatments. Roche utilizes strategic collaborations and investments in R&D to expand its portfolio, while Gilead Sciences emphasizes acquiring smaller biotech firms to enhance its treatment offerings and strengthen its market position.

The startup landscape in the global non-hodgkin lymphoma therapeutics market strategies is witnessing significant growth, with companies focused on pioneering therapies like CAR-T cell treatments, immunotherapies, and precision medicine. These startups are exploring innovative ways to target lymphoma cells, aiming to improve outcomes and reduce treatment side effects, thus contributing to the rapidly evolving and highly competitive non-hodgkin lymphoma therapeutics market.

  • Founded in 2018, Seer Biosciences leverages its innovative Proteograph platform, utilizing proteomics to identify novel biomarkers for cancer, including Non-Hodgkin Lymphoma non-hodgkin lymphoma. By offering deeper insights into the tumor microenvironment, Seer aims to develop more effective, personalized therapies. Their breakthrough innovation in biomarker discovery is expected to refine patient treatment plans, enhancing efficacy while minimizing side effects, providing a significant advancement in the non-hodgkin lymphoma therapeutics space.
  • Established in 2017, ImmunoGenesis is a U.S.-based biotech company focused on developing immune-modulating therapies for Non-Hodgkin Lymphoma (NHL). Their lead candidate, IG-001, is an engineered antibody designed to target immune checkpoints, enhancing T-cell activity against lymphoma cells. The breakthrough lies in its dual-target approach, potentially overcoming resistance seen in current treatments and offering more effective options for patients, improving clinical outcomes in the battle against non-hodgkin lymphoma therapeutics.

Top Player’s Company Profiles

  • Roche (Switzerland) 
  • Novartis (Switzerland) 
  • Gilead Sciences (USA) 
  • Bristol-Myers Squibb (USA) 
  • AbbVie (USA) 
  • Merck & Co. (USA) 
  • AstraZeneca (United Kingdom) 
  • Sanofi (France) 
  • Bayer AG (Germany) 
  • Johnson & Johnson (USA) 
  • Pfizer (USA) 
  • Eli Lilly and Company (USA) 
  • Takeda Pharmaceutical Company Limited (Japan) 
  • Genmab (Denmark) 
  • Seagen Inc. (USA) 
  • Teva Pharmaceutical Industries Ltd. (Israel) 
  • Kyowa Kirin Co., Ltd. (Japan) 
  • Spectrum Pharmaceuticals Inc. (USA) 
  • Autolus Therapeutics (UK) 
  • Immuneel Therapeutics Private Limited (India) 

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 4.37 Billion in 2023 poised to grow from USD 4.62 Billion in 2024 to USD 7.20 Billion by 2032, growing at a CAGR of 5.7% in the forecast period (2025-2032).

The global non-hodgkin lymphoma therapeutics market outlook is highly competitive, with leading players such as Roche, Novartis, Gilead Sciences, and Bristol-Myers Squibb dominating the landscape. These companies focus on innovative therapies, including immunotherapies and CAR-T cell treatments. Roche utilizes strategic collaborations and investments in R&D to expand its portfolio, while Gilead Sciences emphasizes acquiring smaller biotech firms to enhance its treatment offerings and strengthen its market position. 'Roche (Switzerland)', 'Novartis (Switzerland)', 'Gilead Sciences (USA)', 'Bristol-Myers Squibb (USA)', 'AbbVie (USA)', 'Merck & Co. (USA)', 'Celgene Corporation (USA)', 'Amgen (USA)', 'Pfizer (USA)', 'Eli Lilly and Co. (USA)', 'Johnson & Johnson (USA)', 'AstraZeneca (United Kingdom)', 'Sanofi (France)', 'Bayer AG (Germany)', 'Genmab (Denmark)'

The increasing incidence of non-hodgkin lymphoma, driven by aging populations and lifestyle factors, is a key driver for the global non-hodgkin lymphoma therapeutics market trends. As more individuals are diagnosed, there is a greater demand for innovative treatment options, such as immunotherapies, chemotherapy, and targeted therapies, fostering market growth.

Growth of Immunotherapy Approaches in NHL Treatment: Immunotherapy, especially CAR-T cell therapy, is emerging as a significant trend in the non-hodgkin lymphoma therapeutics market. These therapies harness the body’s immune system to target lymphoma cells, offering promising treatment outcomes for patients with relapsed or refractory lymphoma, driving market growth.

What Role do Emission Regulations Play in North American Demand?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Non-Hodgkin Lymphoma Therapeutics Market
Non-Hodgkin Lymphoma Therapeutics Market

Report ID: SQMIG35D2307

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE